On 11 May, Dutch parliament will decide whether to fast track the introduction of the “Wet Homologatie Onderhands Akkoord’, known as ‘WHOA’ or the Dutch Scheme. The legislation would lead to a major improvement of financial restructuring possibilities in the Netherlands for domestic and international companies outside of a formal insolvency procedure.
If successful, the proposed scheme will be introduced by 1 July 2020 combining features from the U.K. Scheme of Arrangements and US Chapter 11 proceedings, while also providing a flexible procedure and limited court involvement.
Based on A&M’s experience, most companies in trouble are not only overleveraged but may also have other operational issues. These issues need to be addressed as part of a parallel operational restructuring process next to a WHOA procedure. For this reason, A&M sees the WHOA procedure as part of a full restructuring process.
Click here to download our insights document.
Digital Deception: Fighting Fraud in the Era of Emerging Technology
August 26, 2025
Davin Teo and Henry Chambers, Managing Directors and Co-leaders of Disputes and Investigations Asia wrote an article on digital deception for the Hong Kong Chartered Governance Institute’s CGj August 2025 issue.
Unlocking Federal Real Estate: Efficiency, Partnerships, and the Path Ahead
August 26, 2025
Managing Director Tom Scott and Senior Director Paul Firth, join George Guszcza, President & CEO of the National Institute of Building Sciences, on The GovNavigators Show to discuss trends, challenges, and opportunities shaping the future of federal real estate.
DOJ and HHS collaborate to enhance False Claims Act prosecution
August 25, 2025
In a recent article for Westlaw Today, Managing Directors Jenelle Beavers and Donald Lochabay explore the U.S. government’s new collaboration and enforcement priorities around the False Claims Act (FCA).
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
